Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of “progression-free survival 2” as a clinical trial end-point

• Meletios A. Dimopoulos,
• Maria T. Petrucci,
• Robin Foà,
• John Catalano,
• Martin Kropff,
• Evangelos Terpos,
• Jingshan Zhang,
• Lara Grote,
• Christian Jacques,
• Antonio Palumbo

Affiliations

Meletios A. Dimopoulos

University of Athens School of Medicine, Greece

Maria T. Petrucci

Sapienza University of Rome, Italy

Robin Foà

Sapienza University of Rome, Italy

John Catalano

Frankston Hospital, Monash University, Victoria, Australia

Martin Kropff

University of Münster, Germany

Evangelos Terpos

University of Athens School of Medicine, Greece

Jingshan Zhang

Celgene Corporation, Summit, NJ, USA

Lara Grote

Celgene Corporation, Summit, NJ, USA

Christian Jacques

Celgene Corporation, Summit, NJ, USA

Antonio Palumbo

University of Turin, Italy